Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Stock Surges 13 Percent on Positive Study Results

NEW YORK, March 27 (GenomeWeb News) - Shares in Sequenom were up 13.29 percent, or $.09, at $.75 in mid-afternoon trading today after the company said two proof-of-concept molecular diagnostic studies using its MassArray system have garnered positive results.

According to Sequenom, the studies, which were performed at different CLIA-certified laboratories, tested for cystic fibrosis and Factor V Leiden and "yielded absolute equivalence of analytical results generated by the MassArray Compact system when compared with well established systems in current use."

 

The studies were conducted and evaluated by Siemens Medical Solutions of Siemens; Specialty Laboratories; and Bioscientia Institut fur Medizinische Diagnostik, and were part of the molecular diagnostics benchmarking study that was initiated in late 2004 by Siemens and Sequenom.

 

As part of the proof-of-concept research, Specialty Laboratories and Bioscientia tested approximately 1,500 DNA samples for Factor V Leiden and Specialty tested more than 1,000 DNA samples for CFTR, according to Sequenom.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.